Meet the Team: Kelly Chamberlain
Kelly Chamberlain has been with Norstella, Evaluate’s parent company as Partner, Market Intelligence since 2024. She’s an expert in supporting competitive intelligence workflows and ensuring that CI teams can maximize the strategic value of market intelligence across cross-functional stakeholder groups. At Norstella, she brings together life science consultants, data scientists, and subject‑matter experts to build […]
BIO-Europe Spring: Pharma Dealmaking in Lisbon
CNS may finally be emerging from its long discussed graveyard. Oncology dealmaking is becoming more selective. And sourcing innovation from China is no longer something to be coy about. These were some of my takeaways from BIO-Europe Spring in Lisbon last week, where the Evaluate team was on the ground sharing data led insight on […]
Three Things we Learned in our 2026 Orphan Drugs Webinar
Orphan drugs are forecast to make up 21% of all prescription drug sales by 2032, according to Evaluate forecasts. So it’s hardly surprising that we had a lot of interest in our latest orphan drugs market webinar. If you missed it, you can find the on-demand version here. If you’re saving that treat for later, […]
Orphan Drugs at a Crossroads: Bigger Numbers, Tougher Calls
Drugs for rare diseases have played an increasingly significant role in the biopharma market for years. I’ve been working on Evaluate’s annual orphan drugs report for the past five years and it’s clear from looking at the evolution of the data in that time that orphans offer considerable opportunity. We’ve just published this year’s report, […]
Three Things we Learned in our 2026 Preview Webinar
Obesity. China. FDA turmoil. Our pharma 2026 Preview webinar was not the place to look for a change in the big pharma buzzwords for this year. These big themes remain with us for now. But there was still plenty for our expert panel to discuss during the session. If you missed it, you can catch […]
A Clearer View from JPM 2026 – Day Four
The final day of JPM 2026 didn’t bring any late-breaking megadeals or big surprise announcements but there was plenty to keep biotech watchers engaged to the end. Our Biomedtracker team has summarized all the presentations in their Day Four report which you can download here, and below are a few highlights to ponder. Large cap […]
A Clearer View from JPM 2026 – Day Three
Day Three of JPM 2026 continued with a sense of both positivity and stability – both noticeably lacking in recent years. Here are a few of the highlights from the Biomedtracker team and you can catch up with all the action from Day Three in our full report which is available here. Mega cap momentum […]
A Clearer View from JPM 2026 – Day Two
Day Two at JPM carried a similar message from Day One: focus where you can win, deploy capital with discipline, and back assets with real clinical traction. Our Biomedtracker team has captured every detail in the full report which is available here, but here are some highlights. Mega caps sharpen their growth engines AstraZeneca’s session […]
A Clearer View from JPM 2026 – Day One
Here we are again. January means the JP Morgan Healthcare Conference and all eyes in the pharma and biotech space turn to San Francisco. Our Biomedtracker team is providing daily reports to bring you the highlights of each day’s activities. There’s loads to digest in the full Day One report, so here are a few […]
How Biotechs Can Win Capital in 2026: Highlights from Evaluate’s Financing Forum
January may be upon us but allow me one chance to look back at one of December’s highlights; Evaluate’s event that took place in London. Evaluate Financing Forum: Biotech Strategies for Accessing Capital saw more than 50 professionals from pharma, biotech and financing come together for a morning of networking and knowledge sharing about biotech […]
